SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innovator ETFs Trust - Innovator U.S. Equity Buffer ETF - September

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2026 High Yield Corporate Bond ETF

Invesco BulletShares 2026 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2027 High Yield Corporate Bond ETF

Invesco BulletShares 2027 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2028 High Yield Corporate Bond ETF

Invesco BulletShares 2028 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2026 Municipal Bond ETF

Invesco BulletShares 2026 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2027 Municipal Bond ETF

Invesco BulletShares 2027 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2028 Municipal Bond ETF

Invesco BulletShares 2028 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2029 Municipal Bond ETF

Invesco BulletShares 2029 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2030 Municipal Bond ETF

Invesco BulletShares 2030 Municipal Bond ETF

BlackRock ETF Trust - iShares U.S. Thematic Rotation Active ETF

BlackRock ETF Trust - BlackRock Future U.S. Themes ETF

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) released its earnings results on Tuesday. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). The business had revenue of $6.56 million for the quarter, compared to the consensus...

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -3.35% and -35.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire...

IDEAYA Biosciences (IDYA) Projected to Post Earnings on Monday

IDEAYA Biosciences (NASDAQ:IDYA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., May 1, 2026 SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ --IDEAYA Biosciences...

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 28.9% in the fourth quarter, according to its most recent Form 13F filing...

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program IDEAYA...

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%  - Here's Why

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5% - Time to Sell...

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma IDEAYA Biosciences Announces Late-Breaking...

IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded IDEAYA Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Stocktwits

Stocktwits Polls

Current Price	$28.32
Prev Close	$28.24
Open	$28.20
Dividend Yield	0.00%
50-Day Moving Average	$31.78
Beta	1.15
Avg. Volume	1.71M
PE Ratio	-17.73

52-Week High	$39.28
52-Week Low	$16.84
Market Capitalization	$2.49B
EPS (Annual)	-$1.28
Price to Book	2.65
Revenue Per Employee	$1.51M

IDYA
Ideaya Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IDYA News

IDYAIdeaya Biosciences Inc